Clinical Trial

A Clinical Study to Evaluate SM17 in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I study in Chinese healthy adult volunteer participants. It aims to evaluate the safety, tolerability, PK profile and immunogenicity of a single dose of SM17 SC in healthy Chinese adult participants. It also aims to evaluate the bioavailability of SM17 SC compared to SM17 IV.
Protocol Amendment History 2 changes
critical Trial completed 2026-04-07
minor Completion moved earlier: 2026-03-06 -> 2026-02-03 2026-04-07
Trial Details
NCT Number NCT07466940
Lead Sponsor SinoMab BioScience Ltd
Conditions Atopic Dermatitis, Asthma, Inflammatory Bowel Disease
Enrollment 30 participants
Start Date 2025-10-14
Primary Completion 2026-02-03 (estimated)
Study Completion 2026-02-03 (estimated)
Updated on ClinicalTrials.gov 2026-04-06